Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,088 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,119
- Phase 1824
- Phase 1/Phase 2483
- Phase 3350
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma334
- Acute Myeloid Leukemia291
- Lymphoma183
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Anemia62
- Mantle Cell Lymphoma62
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center59
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama147
- Arizona123
- Florida110
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,088 total
- NCT03541889RecruitingPhase 1
Tracking blood stem cell transplant success with special imaging
This study uses a safe PET scan–type imaging test to look for signs that a stem cell transplant has “taken” (engrafted). It may help doctors understand why some transplants fail and how to improve chances of success.
Atlanta, GeorgiaAges 4–80 - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Duarte, CaliforniaAges 18 years+ - NCT07619287RecruitingPhase 1
Testing BG-75202 for blood cancers that came back
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
Concord, New South WalesAges 18 years+ - NCT06292780RecruitingPhase 1/Phase 2
Testing linvoseltamab for AL amyloidosis that came back
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT05651932RecruitingPhase 1
Test of an MMSET inhibitor for relapsed multiple myeloma
This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.
San Francisco, CaliforniaAges 18 years+ - NCT07012109RecruitingPhase 1
A trial of BEBT-507 for people with polycythemia vera
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06998641Recruiting
Chitosan gauze for bleeding tears after childbirth
This trial tests whether a special gauze made with chitosan (a natural substance that helps blood clot) can stop bleeding from minor tears after childbirth without needing stitches. It may offer a simpler, gentler option for women with small tears.
IstanbulAges 18–48 - NCT07285239RecruitingPhase 3
Comparing two drug combinations for newly diagnosed multiple myeloma
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
La Crosse, WisconsinAges 18–79 - NCT07209371RecruitingPhase 2
Rifaximin vs no treatment for early blood protein disorder
This study tests whether an antibiotic called rifaximin can lower the abnormal protein levels in people with MGUS (a condition that can sometimes lead to blood cancers). If it works, it might help keep MGUS from getting worse.
Seattle, WashingtonAges 18 years+ - NCT06819865Recruiting
EkoSonic device for acute pulmonary embolism in Chinese patients
This study tests if the EkoSonic device (used with a clot-busting medicine) is safe and effective for treating acute pulmonary embolism. It may be an option for people who have a large clot and an enlarged right heart chamber.
Guangzhou, GuangdongAges 18 years+ - NCT07282210RecruitingPhase 2
New medicine for sickle cell hemolysis
This trial tests a new medicine (SIL-8301) to help control red blood cell breakdown (hemolysis) in people with sickle cell disease. It is for those who are already taking hydroxyurea and have had few pain crises but still have complications from hemolysis.
Toronto, OntarioAges 16–35 - NCT06218602RecruitingPhase 2
Fecal transplant for lymphoma patients getting CAR T therapy
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Houston, TexasAges 18 years+ - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Phoenix, ArizonaAges Any age - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Berkeley, CaliforniaAges 18 years+ - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Orange, CaliforniaAges 18–75 - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT06605378Recruiting
Antibody and cytokine study for people with CGD
This study is checking levels of antibodies and immune-signaling molecules (cytokines) in people with chronic granulomatous disease (CGD). It aims to better understand the immune system in CGD, which may help with future treatments.
Montgomery, AlabamaAges Any age - NCT06519422RecruitingPhase 3
Tranexamic acid for anaemia in women
This trial tests whether tranexamic acid, a medicine that helps reduce bleeding, can improve anaemia (low blood iron) in women with heavy periods. If you have anaemia and heavy menstrual bleeding, this treatment might help raise your iron levels.
Ibadan, Oyo StateAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,088 recruiting hematology studies from the U.S. registry right now, out of 7,677 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.